Poxel

Merck Patent Gmbh

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Merck Patent Gesellschaft MIT Beschrankter Haftung

Universite Claude Bernard – Lyon1

Ens-ecole Normale Superieure De Lyon

Edelris

Poxel Sa

Sophie Hallakou-Bozec

Daniel Cravo

Franck F Lepifre

Christine G Charon

Sébastien Bolze

Didier Roche

Patrice Andre

Jean-Denis Durand

Amaury Patin

Laurent Faveriel

Marine Gilardone

Denis Carniato

Gérard Moinet

Vincent Lotteau

Melanie Schultz

Bjoern Hock

Pascale Fouqueray

Didier Mesangeau

Samer Elbawab

Oliver Poeschke

Pauline Radreau

Dominique Marais

Franck Lepifre

The invention relates to the use of a thienopyridone derivative, or a pharmaceutical composition comprising the same, in the treatment of genetic neurodegenerative diseases selected from adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN).

Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy

The present invention provides a method for treating or preventing heart failure with preserved ejection fraction (HFPEF), wherein the method comprises administering to a patient having or at risk of developing HFPEF a therapeutically effective amount of imeglimin.

Methods of treating heart failure with preserved ejection fraction

The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.

Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection

Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection

The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases. 

Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof

Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies. 

Thienopyridone derivatives useful as activators of AMPK

The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives. 

Treatment of type 1 diabetes

The invention relates to compounds of formula (I) wherein the radicals Rto Rhave the meaning according to claim, and/or physiologically acceptable salts thereof, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with the activity of AMP-activated protein kinase (AMPK). Another object of the invention concerns the use of said compounds for enhancing glucose homeostasis, improving podocytopathy and/or decreasing the production of reactive oxygen species (ROS). The invention also relates to a method for in-vitro diagnosing diabetic nephropathy and a method for screening compounds that reduce podocytopathy, in each case by applying synaptopodin as biomarker. 

Tetrahydrotriazine compounds for treating diseases associated with AMPK activity

The present invention relates to compounds of formula (I) wherein X, Y, Z, R, R, Rare as defined in claim, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.

Quinoxalinedione derivatives useful as activators of AMPK-activated protein kinase

The present invention relates to compounds of formula (I) wherein R, Rand B, Bare as defined in claim, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I). 

Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators

The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I). 

The present invention relates to 7-azaindole derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11&#x3b2;-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. 

7-azaindole derivatives as selective 11-&#x3b2;-hydroxysteroid dehydrogenase type 1 inhibitors

The present invention relates to compounds of formula (I)  wherein X, Y, Z, R, R, Rare as defined in claim, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.

Quinoxalinedione derivatives which are activators of AMPK-activated protein kinase

The invention relates to the use of imidazole derivatives of the formula (1): in which A, R', R&#x2032;and R&#x2032;are as defined in the description, as AMPK activators. The invention also relates to processes for the preparation of the said compounds, to their uses for the preparation of medicaments for the treatment of insulin resistance, diabetes and related pathologies, and also obesity, and to the pharmaceutical compositions comprising them. Certain compounds of the formula (1) are novel and, in this respect, also form part of the invention.

Growing community of inventors

Montrouge, France

Sophie Hallakou-Bozec